Ronald Duncan, MD
Emergency Medicine · Elwood, INNPI 1629090980
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Among emergency medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$873
- AbbVie$757
- Pfizer$635
- Bayer$500
- Lilly USA, LLC$446
- Dexcom, Inc.$345
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,67598%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $873 |
| AbbVie | 60 | $757 |
| Pfizer | 47 | $635 |
| Bayer | 29 | $500 |
| Lilly USA, LLC | 31 | $446 |
| Dexcom, Inc. | 18 | $345 |
| Novo Nordisk | 22 | $315 |
| Boehringer Ingelheim | 16 | $242 |
| Amgen | 11 | $199 |
| Exact Sciences | 10 | $169 |
| Abbott | 7 | $154 |
| Astellas Pharma US Inc | 6 | $153 |
| GSK | 8 | $117 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $113 |
| Idorsia Pharmaceuticals US Inc | 5 | $96 |
| Sanofi-aventis U.S. LLC | 7 | $92 |
| E.r. Squibb & Sons, L.L.C. | 6 | $92 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Johnson & Johnson | 4 | $66 |
| Corcept Therapeutics | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Lundbeck LLC | 1 | $35 |
| Ascensia Diabetes Care US Inc. | 1 | $32 |
| Verona Pharma, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Merck | 1 | $11 |
| Phathom Pharmaceuticals, Inc. | 1 | $8 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$5,786 in reported general payments places this provider in the 95th percentile of 1,073 emergency medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $205,100 |
| EliquisApixaban | 190 | $148,443 |
| JardianceEmpagliflozin | 114 | $108,992 |
| TrulicityDulaglutide | 48 | $70,330 |
| FarxigaDapagliflozin Propanediol | 76 | $58,201 |
| ForteoTeriparatide | 11 | $46,245 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $39,538 |
| TradjentaLinagliptin | 40 | $31,167 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $24,886 |
| LinzessLinaclotide | 27 | $23,625 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $23,305 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $16,662 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $16,625 |
| MyrbetriqMirabegron | 33 | $16,349 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $15,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $315 | $205,100166 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $242 | $165,649188 claims |
| PfizerEliquis, Abrysvo | $635 | $160,918229 claims |
| Lilly USA, LLCTrulicity, Forteo, Mounjaro | $446 | $130,14472 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix | $117 | $87,691154 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $873 | $69,31991 claims |
| AbbVieLinzess | $757 | $23,62527 claims |
| Astellas Pharma US IncMyrbetriq | $153 | $16,34933 claims |
| Johnson & JohnsonXarelto | $66 | $11,02217 claims |
| MerckJanuvia | $11 | $7,92814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,073 emergency medicine providers in Indiana.
Other emergency medicine in Elwood
- Roy AbrahamPortland$80K
- Michael MartinoBedford$67K
- Andrew OfferleFort Wayne$40K
- Dustin HollandIndianapolis$39K
- Peter PangIndianapolis$23K
- Robinson FerreIndianapolis$16K
- Daren BeamIndianapolis$13K
- Jeffrey KlineIndianapolis$12K
- Kristen ErnstingIndianapolis$11K
- Marc EstesFrankfort$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.